BPC 157: The peptide with big claims and scant evidence STAT The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Why Are People Injecting Themselves with Peptides? The New Yorker BPC 157 Arginate Therapy for your Healing Simply Wellness